Image de couverture de livre

A sex‐specific “hormone–bone–brain” axis in Alzheimer's disease: Integrating Global Burden of Disease data and Mendelian randomization analysis to reveal the causal role of osteocalcin

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Zhiyang Zheng, Yifan Ren, Jingzhe Gao, Jianglong Chen, Ke Yuan, Zhongqiang Zhang, Zhigang Wang, Xia Lei, Yafeng Zhang, Hao Ai, Fang Geng, Ning Zhang, Hongdan Xu
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Alzheimer's & Dementia: Translational Research & Clinical Interventions
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

APOE ‐associated disease risk and sex‐specific effects in Egyptian Alzheimer's disease: an exploratory study
par: Mai Othman, et autres
Publié: (2026)

Association of region‐specific hippocampal reduction of neurogranin with inflammasome proteins in post mortem brains of Alzheimer's disease
par: Regina T. Vontell, et autres
Publié: (2024)

Mapping sex differences in brain and cognition in relation to APOE ε4 and amyloid burden: A longitudinal normative modelling study
par: Sivaniya Subramaniapillai, et autres
Publié: (2026)

Association of allostatic load with all‐cause and cause‐specific dementia: A prospective cohort study
par: Yifan Gou, et autres
Publié: (2025)

Genetically proxied IL‐6 signaling and risk of Alzheimer's disease and lobar intracerebral hemorrhage: A drug target Mendelian randomization study
par: Evangelos Pavlos Myserlis, et autres
Publié: (2024)

Mapping brain change longitudinally: physical activity intervention reshapes structural alterations and functional connectivity in Alzheimer's disease
par: Ravi Dadsena, et autres
Publié: (2026)

Distribution of insulin in primate brain following nose‐to‐brain transport
par: Kylie Smith, et autres
Publié: (2024)

Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
par: Valentina Di Caro, et autres
Publié: (2025)

Study of the utility and impact of a plasma p‐tau181 Alzheimer's biomarker (SUITABLE)
par: Kyra O'Brien, et autres
Publié: (2026)

Real‐world relationship between blood biomarker‐based PhenoAge, metformin, and Alzheimer's disease
par: Yi Shi, et autres
Publié: (2026)

Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease
par: Ralph Kern, et autres
Publié: (2025)

Mitochondrial blood‐based biomarker is related to cardiorespiratory fitness and aging in a sex‐dependent manner
par: Riley E. Kemna, et autres
Publié: (2025)

Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
par: Luke E. Stoeckel, et autres
Publié: (2025)

New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop
par: Maria A. Telpoukhovskaia, et autres
Publié: (2024)

Researcher photographs in recruitment materials to increase willingness to participate in brain health research
par: Christy J. W. Ledford, et autres
Publié: (2026)

Exploring small‐world brain connectivity in aging and its relationship with cognitive reserve
par: Chiara Pappalettera, et autres
Publié: (2026)

Critical evaluation of real‐world evidence of repurposable medicines in the Alzheimer's disease drug development pipeline using a target trial emulation
par: Reina Tonegawa‐Kuji, et autres
Publié: (2025)

Blood DNA methylation signature of cognitive reserve moderates the association between CSF tau pathology and memory in prodromal Alzheimer's disease
par: David Lukacsovich, et autres
Publié: (2026)

Building digital solutions to support brain health prescribing in primary care: Where to begin?
par: Joyce Siette, et autres
Publié: (2024)

Association between 24‐h time‐use composition and brain age: The IGNITE study
par: Audrey M. Collins, et autres
Publié: (2025)

Alzheimer's disease drug development pipeline: 2026
par: Jeffrey L. Cummings, et autres
Publié: (2026)

Biomarkers in Alzheimer's disease clinical trials: 2025
par: Amanda M. Leisgang Osse, et autres
Publié: (2026)

Alzheimer's disease drug development pipeline: 2025
par: Jeffrey L. Cummings, et autres
Publié: (2025)

Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease–related cognitive decline
par: Yuan Shang, et autres
Publié: (2025)

Response to: Refining the clinical interpretation of activity variability in cognitive impairment: The need for phenotypic specificity
par: Patrick T. Donahue, et autres
Publié: (2025)

Genetic associations with psychosis and affective disturbance in Alzheimer's disease
par: Inga Margret Antonsdottir, et autres
Publié: (2024)

Why testing and diagnosis for Alzheimer's disease are mission critical
par: Brent W. Beasley
Publié: (2025)

Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease
par: Steven E. Arnold, et autres
Publié: (2024)

Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease
par: Garrett R. Mullins, et autres
Publié: (2025)

Awareness and cognitive rehabilitation in Alzheimer's disease and frontotemporal dementia
par: Eric Salmon, et autres
Publié: (2024)

Alzheimer's disease drug development in an evolving therapeutic landscape
par: Stacie Weninger, et autres
Publié: (2024)

Implications of practice effects for the design of Alzheimer clinical trials
par: Jasmin A. Duehring, et autres
Publié: (2025)

Recruitment and Retention for Alzheimer's Disease Diversity Genetic Cohorts in the ADSP (READD‐ADSP): A global effort to identify genetic factors in Alzheimer's disease
par: Rufus Akinyemi, et autres
Publié: (2025)

Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials
par: Susanna Gobbi, et autres
Publié: (2026)

Developing educational materials to aid in Alzheimer's blood biomarker disclosure
par: Raymond R. Romano, et autres
Publié: (2025)

Alzheimer's disease Stage 1 and 2: Biology, diagnostics, and treatment
par: Suzanne E. Schindler, et autres
Publié: (2026)

Sex differences and the role of estrogens in the immunological underpinnings of Alzheimer's disease
par: Brittani R. Price, et autres
Publié: (2025)

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting
par: Ronald C. Petersen, et autres
Publié: (2025)

Uncovering barriers to early diagnosis of Alzheimer's disease: a European perspective
par: David A. Pérez‐Martínez, et autres
Publié: (2025)

Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease
par: Maria L. Faquetti, et autres
Publié: (2024)